Ken Griffin Glaukos Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Glaukos Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 27,800 shares of GKOS stock, worth $4.19 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

27,800

Previous 21,600 28.7%

Holding current value

$4.19 Million

Previous $2.56 Million 41.67%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$113.62 - $135.39 $19.2 Million - $22.9 Million	-169,286 Reduced 32.02%	359,447 $46.8 Million
Q2 2024 Aug 14, 2024	BUY	$89.48 - $118.35 $44.1 Million - $58.3 Million	492,785 Added 1370.83%	528,733 $62.6 Million
Q1 2024 May 15, 2024	SELL	$76.4 - $96.33 $6.34 Million - $8 Million	-83,013 Reduced 69.78%	35,948 $3.39 Million
Q4 2023 Feb 14, 2024	SELL	$59.53 - $85.11 $14.7 Million - $21 Million	-246,679 Reduced 67.46%	118,961 $9.46 Million
Q3 2023 Nov 14, 2023	SELL	$69.23 - $79.09 $4.76 Million - $5.44 Million	-68,821 Reduced 15.84%	365,640 $27.5 Million
Q2 2023 Aug 14, 2023	SELL	$45.44 - $71.21 $14.7 Million - $23.1 Million	-323,863 Reduced 42.71%	434,461 $30.9 Million
Q1 2023 May 15, 2023	BUY	$43.88 - $52.48 $2.51 Million - $3 Million	57,141 Added 8.15%	758,324 $38 Million
Q4 2022 Feb 14, 2023	BUY	$40.82 - $57.75 $1.35 Million - $1.91 Million	33,001 Added 4.94%	701,183 $30.6 Million
Q3 2022 Nov 14, 2022	BUY	$46.84 - $58.49 $30.9 Million - $38.6 Million	660,498 Added 8595.76%	668,182 $35.6 Million
Q2 2022 Aug 15, 2022	SELL	$34.86 - $63.77 $1.65 Million - $3.02 Million	-47,361 Reduced 86.04%	7,684 $349,000
Q1 2022 May 16, 2022	SELL	$44.33 - $57.82 $501,904 - $654,638	-11,322 Reduced 17.06%	55,045 $3.18 Million
Q4 2021 Feb 14, 2022	SELL	$40.27 - $56.99 $9.14 Million - $12.9 Million	-227,022 Reduced 77.38%	66,367 $2.95 Million
Q3 2021 Nov 15, 2021	BUY	$47.43 - $84.23 $11.3 Million - $20.1 Million	238,534 Added 434.84%	293,389 $14.1 Million
Q2 2021 Aug 16, 2021	SELL	$73.06 - $97.7 $10.6 Million - $14.1 Million	-144,748 Reduced 72.52%	54,855 $4.65 Million
Q1 2021 May 17, 2021	BUY	$70.43 - $97.42 $9.24 Million - $12.8 Million	131,182 Added 191.73%	199,603 $16.8 Million
Q4 2020 Feb 16, 2021	SELL	$48.9 - $75.26 $4.84 Million - $7.44 Million	-98,899 Reduced 59.11%	68,421 $5.15 Million
Q3 2020 Nov 16, 2020	SELL	$37.23 - $50.97 $18.2 Million - $24.9 Million	-488,595 Reduced 74.49%	167,320 $8.29 Million
Q2 2020 Aug 14, 2020	BUY	$28.78 - $46.83 $9.75 Million - $15.9 Million	338,741 Added 106.8%	655,915 $25.2 Million
Q1 2020 May 15, 2020	BUY	$25.53 - $70.14 $5.61 Million - $15.4 Million	219,561 Added 224.93%	317,174 $9.79 Million
Q4 2019 Feb 14, 2020	SELL	$54.18 - $65.64 $17.5 Million - $21.2 Million	-323,474 Reduced 76.82%	97,613 $5.32 Million
Q3 2019 Nov 14, 2019	BUY	$58.58 - $83.91 $17.7 Million - $25.3 Million	301,843 Added 253.13%	421,087 $26.3 Million
Q2 2019 Aug 14, 2019	BUY	$63.59 - $78.71 $6.93 Million - $8.57 Million	108,939 Added 1057.15%	119,244 $8.99 Million
Q1 2019 May 15, 2019	SELL	$50.75 - $80.54 $859,146 - $1.36 Million	-16,929 Reduced 62.16%	10,305 $0
Q4 2018 Feb 14, 2019	BUY	$52.18 - $67.93 $441,755 - $575,095	8,466 Added 45.11%	27,234 $1.53 Million
Q3 2018 Nov 13, 2018	BUY	$38.13 - $68.37 $369,327 - $662,231	9,686 Added 106.65%	18,768 $0
Q2 2018 Aug 10, 2018	BUY	$27.62 - $44.51 $250,844 - $404,239	9,082 New	9,082 $0
Q4 2017 Feb 09, 2018	SELL	$24.5 - $36.01 $410,816 - $603,815	-16,768 Closed	0 $0
Q3 2017 Nov 09, 2017	BUY	$31.26 - $42.03 $524,167 - $704,759	16,768	16,768 $553,000

Others Institutions Holding GKOS

# of Institutions

341

Shares Held

46.8M

Call Options Held

132K

Put Options Held

188K

View Full List

About GLAUKOS Corp

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.18B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

More about GKOS

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account